Ondine Biomedical Inc.
OBI.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | £43,227 | £29,078 | £65,286 | £184,744 |
| - Cash | £9,767 | £2,981 | £13,125 | £30,365 |
| + Debt | £168 | £541 | £896 | £739 |
| Enterprise Value | £33,628 | £26,638 | £53,057 | £155,118 |
| Revenue | £2,049 | £1,203 | £638 | £2,569 |
| % Growth | 70.3% | 88.6% | -75.2% | – |
| Gross Profit | £1,321 | £703 | £287 | £1,254 |
| % Margin | 64.5% | 58.4% | 45% | 48.8% |
| EBITDA | -£18,486 | -£13,787 | -£18,849 | -£48,359 |
| % Margin | -902.2% | -1,146.1% | -2,954.4% | -1,882.4% |
| Net Income | -£19,098 | -£14,412 | -£19,372 | -£50,085 |
| % Margin | -932.1% | -1,198% | -3,036.4% | -1,949.6% |
| EPS Diluted | -0.07 | -0.073 | -0.1 | -0.26 |
| % Growth | 4.2% | 26.9% | 61.5% | – |
| Operating Cash Flow | -£15,490 | -£13,653 | -£16,345 | -£12,540 |
| Capital Expenditures | -£10 | -£177 | -£311 | -£77 |
| Free Cash Flow | -£15,500 | -£13,830 | -£16,656 | -£12,617 |